An observational study in Vitiligo Vulgaris, sponsored by St. Luke's-Roosevelt Hospital Center. Completed at 2 sites in United States. Per ClinicalTrials.gov, last updated 2015-05-25.
Sponsored by St. Luke's-Roosevelt Hospital Center · Observational
Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.
Patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo.
298 studies on the registry are indexed under Vitiligo; 69 are open to participants now.
This study's enrollment of 57 is below the median of 111 across 60 observational studies indexed under Vitiligo.
Browse Vitiligo studies →St. Luke's-Roosevelt Hospital Center is the lead sponsor of 68 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients willing to sign consent, complete questionnaire and/ or laboratory studies.
Exclusion Criteria:
Quality of life disturbances in people with vitiligo
dermatology life quality indices were you used and correlated with location of disease
Time frame: point prevalence
self-reporting of vitiligo disease symptoms and history
Correlation of the patient survey response with chart documentation was performed.
Time frame: single survey
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Luke's-Roosevelt Hospital Center